- Home
- PROK vs ELDN Comparison
PROK vs ELDN Comparison
Compare PROK & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PROK | ELDN |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | 231 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.5M | 291.8M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PROK | ELDN |
|---|---|---|
| Price | $1.68 | $3.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $7.40 | ★ $8.50 |
| AVG Volume (30 Days) | 682.4K | ★ 1.7M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $893,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1075.00 | N/A |
| 52 Week Low | $0.54 | $1.35 |
| 52 Week High | $7.13 | $4.60 |
Technical Indicators
Market Signals| Indicator | PROK | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 56.57 |
| Support Level | $1.56 | $2.45 |
| Resistance Level | $2.58 | $4.60 |
| Average True Range (ATR) | 0.10 | 0.21 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 22.50 | 58.72 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.